Telik announces start of phase 1-2a clinical study of Telintra tablets

By Elaine Rigoli

Tampa, Fla., Feb. 22 - Telik, Inc. announced Wednesday that the company will begin a multi-center, phase 1-2a clinical study to evaluate the tolerability and pharmcokinetics of Telintra tablets in patients with myelodysplastic syndrome, a common blood disorder in the elderly that originates in stem cells.

If successfully developed, this oral formulation may support the evaluation of Telintra in additional blood disorders characterized by low levels of one or more of the three blood cell lineages, according to a company news release.

The Telintra tablets trial follows the recently completed positive phase 2 trial of the parenteral formulation of Telintra in myelodysplastic syndrome.

The trial observed high levels of bilineage and trilineage hematologic improvement assessed by the standard International Working Group response criteria for myelodysplastic syndrome, according to the release.

Responses were observed in patients with low, intermediate and high-risk syndrome.

Telintra is a small molecule product candidate that has been shown to have myelorestorative activity when administered orally or by infusion in preclinical testing. It was discovered using Telik's TRAP small molecule drug discovery technology, according to the release.

Telik is a biopharmaceutical company that develops and markets small molecule drugs to treat serious diseases. The company is based in Palo Alto, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.